Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Effects of maternal e-cigarette aerosol exposure on nicotine's addiction-related behavioral and neurobiological effects in offspring

Award Number: R01DA060187
ORGANIZATION: NATIONAL INSTITUTE ON DRUG ABUSE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 03/15/2025
PERIOD OF PERFORMANCE END DATE: 12/31/2029

Group Awards By:

View Award Description

Effects of maternal e-cigarette aerosol exposure on nicotine's addiction-related behavioral and neurobiological effects in offspring - SUMMARY/ABSTRACT The goal of this project is to use animal models to understand how maternal exposure to electronic nicotine delivery system (ENDS) aerosols during pregnancy adversely impacts addiction-related behaviors and reinforcement-related neurocircuitry in offspring. An increasing number (up to 15%) of pregnant women are using ENDS, exposing several hundred thousand fetuses per year in the U.S. alone. Combustible cigarettes have long-term developmental consequences in offspring including increased risk of impulsivity-related disorders such as attention deficit hyperactivity disorder (ADHD) and addiction to tobacco. These adverse effects are generally attributable to nicotine, but other toxicants in tobacco smoke may also play a role. Although ENDS contain lower levels of many of those toxicants, ENDS can deliver as much or more nicotine as combustible cigarettes, and contain additional chemicals (e.g., propylene glycol, ethanol, unique flavorants, toxic byproducts) that are not present in tobacco or tobacco smoke. Thus, ENDS use may pose not only many of the same risks to pregnant women and their children as smoking, but unique risks as well. These issues have received only limited attention, leaving the adverse effects of ENDS use during pregnancy largely unknown. Research to date shows that prenatal ENDS exposure in rodents has adverse effects on several behavioral and genetic outcomes in offspring that are attributable to nicotine and/or non-nicotine constituents in ENDS. However, no studies have examined other potential adverse outcomes, such as increased impulsivity or abuse liability of nicotine and associated adaptations in reinforcement-related circuitry. To address this issue, this project will examine the effects of maternal inhalational exposure to commercial ENDS aerosols (fruit- and tobacco-flavor) on these outcomes in rat offspring. Endpoints will include measures of impulsive action and impulsive choice (Aim 1), nicotine abuse liability in nicotine self-administration models (Aim 2), and function of reinforcement-related neurocircuitry following acute or chronic nicotine in intracranial self-stimulation models (Aim 3). Cell-specific changes in gene expression and chromatin accessibility, as well as degree of nAChR upregulation, in key reinforcement-related mesocorticolimbic areas (NAc, PFC), will also be analyzed to examine potential neurobiological mechanisms mediating behavioral effects in these and other studies and generate hypotheses for future studies (Aim 4). Inclusion of nicotine-free ENDS aerosol and aerosolized nicotine alone will allow us to assess the relative contribution of nicotine versus other constituents in the effects of nicotine-containing ENDS aerosol. Given the ability of certain non-nicotine constituents in ENDS aerosol to enhance the effects of nicotine or produce adverse prenatal effects of their own, our overall hypothesis is that prenatal exposure to nicotine- containing ENDS aerosol will produce greater adverse effects than the other exposure conditions. Findings will provide new information to the public and the FDA on the potential risks of ENDS use during pregnancy and suggest neural mechanisms of interest for future preclinical studies and brain imaging studies in humans.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $709,610 )
2026	2026	HENNEPIN HEALTHCARE RESEARCH INSTITUTE	701 PARK AVE	MINNEAPOLIS	MN	55415	HENNEPIN	USA	Drug Use and Addiction Research Programs	000	2	2/27/2026	NON-COMPETING CONTINUATION	$709,610
														Subtotal = $709,610

Issue Date FY: 2025 ( Subtotal = $692,419 )
2025	2025	HENNEPIN HEALTHCARE RESEARCH INSTITUTE	701 PARK AVE	MINNEAPOLIS	MN	55415	HENNEPIN	USA	Drug Use and Addiction Research Programs	000	1	3/10/2025	NEW	$623,177
2025	2025	HENNEPIN HEALTHCARE RESEARCH INSTITUTE	701 PARK AVE	MINNEAPOLIS	MN	55415	HENNEPIN	USA	Drug Use and Addiction Research Programs	001	1	5/16/2025	NEW	$69,242
														Subtotal = $692,419

Grand Total All Awards = $1,402,029

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Effects of maternal e-cigarette aerosol exposure on nicotine's addiction-related behavioral and neurobiological effects in offspring

Award Number: R01DA060187

ORGANIZATION: NATIONAL INSTITUTE ON DRUG ABUSE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 03/15/2025

PERIOD OF PERFORMANCE END DATE: 12/31/2029

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer